Xeris Biopharma Holdings Inc - Çeyreklik Nakit Akışı (NASDAQ:XERS) | MetaTrader

Tam grafiği aç

Financials

Genel Bakış Tablolar İstatistikler

Çeyreklik Yıllık

Toplam varlıklar 323.06 M315.45 M334.69 M370.19 M383.53 M Toplam yükümlülükler 352.68 M350.58 M353.99 M371.05 M369.84 M Total equity -29.61 M-35.13 M-19.3 M-861 K13.69 M Total liabilities & shareholders' equities 323.06 M315.45 M334.69 M370.19 M383.53 M Total debt 232.11 M229.76 M218.63 M219.47 M220.34 M Net debt 160.49 M171.32 M159.34 M127.87 M109.29 M

Haberler

Barclays, Xeris Pharmaceuticals hissesi için hedefini korudu

Xeris Pharmaceuticals Barclays’te: RECORLEV Güçlü Büyümeyi Destekliyor

Xeris Pharmaceuticals at Barclays: Strong Growth Fueled by RECORLEV

Xeris Biopharma Holdings, Inc. (XERS) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Xeris Biopharma (XERS) Reports Q4 Earnings: What Key Metrics Have to Say

Xeris Biopharma (XERS) Q4 Earnings and Revenues Surpass Estimates

Xeris Biopharma hisseleri 4Ç kazanç sonrası yükselişte

Xeris Biopharma stock up nearly 3% after Q4 EPS beat, above estimate guidance

Xeris Pharmaceuticals kazancı $0,04 ile beklentilere göre daha iyi, kâr ise beklentilere göre yüksek

Xeris Pharmaceuticals earnings beat by $0.04, revenue topped estimates

Xeris Pharmaceuticals büyüme hızlanırken kazanç testinde

Xeris Pharmaceuticals faces earnings test as growth accelerates